James R. Wright

54.7k total citations · 3 hit papers
1.0k papers, 39.1k citations indexed

About

James R. Wright is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, James R. Wright has authored 1.0k papers receiving a total of 39.1k indexed citations (citations by other indexed papers that have themselves been cited), including 346 papers in Pulmonary and Respiratory Medicine, 299 papers in Molecular Biology and 192 papers in Oncology. Recurrent topics in James R. Wright's work include Chronic Obstructive Pulmonary Disease (COPD) Research (78 papers), Pancreatic function and diabetes (64 papers) and Lung Cancer Treatments and Mutations (54 papers). James R. Wright is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (78 papers), Pancreatic function and diabetes (64 papers) and Lung Cancer Treatments and Mutations (54 papers). James R. Wright collaborates with scholars based in Canada, United States and United Kingdom. James R. Wright's co-authors include Andrew Churg, T. To, Dianne Groll, Claire Bombardier, Hsin Tai, Changshi Xie, James C. Hogg, Manuel G. Cosío, Peter D. Paré and Ajay Bakhshi and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

James R. Wright

1.0k papers receiving 37.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18

1985 974 citations James R. Wright et al. profile →
The development of a comorbidity index with physical function as the outcome

2005 956 citations James R. Wright et al. profile →
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

2021 170 citations James R. Wright et al. profile →

Peers

Countries citing papers authored by James R. Wright

Since Specialization

Citations

This map shows the geographic impact of James R. Wright's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James R. Wright with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James R. Wright more than expected).

Fields of papers citing papers by James R. Wright

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James R. Wright. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James R. Wright. The network helps show where James R. Wright may publish in the future.

Co-authorship network of co-authors of James R. Wright

This figure shows the co-authorship network connecting the top 25 collaborators of James R. Wright. A scholar is included among the top collaborators of James R. Wright based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James R. Wright. James R. Wright is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	How to Evaluate Behavioral Models 2024 ·Proceedings of the AAAI Conference on Artificial Intelligence ·(unknown), (unknown), Kevin Leyton‐Brown, James R. Wright	1
2	The balance of evidence on 100% juice & health: A systematic umbrella review of meta-analyses 2024 ·Proceedings of The Nutrition Society ·Emma Beckett, Flávia Fayet‐Moore, Tim Cassettari, Carlene Starck, James R. Wright, Michelle Blumfield	1
3	A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer. 2024 ·Journal of Clinical Oncology ·Thatcher Heumann, Mark Yarchoan, (unknown), Jiayun Lu, Daneng Li, Paul R. Kunk, Renuka Iyer, Farshid Dayyani, Lionel Aurelien Kankeu Fonkoua, (unknown), Olumide B. Gbolahan, Milind Javle, S. Lindsey Davis, Vaia Florou, James R. Wright, Elad Sharon, Hao Wang, Gregory B. Lesinski, Nilofer S. Azad	3
4	Pathologic Criteria for the Diagnosis of Usual Interstitial Pneumonia vs Fibrotic Hypersensitivity Pneumonitis in Transbronchial Cryobiopsies 2023 ·Modern Pathology ·Andrew Churg, Henry D. Tazelaar, Radoslav Matěj, Martina Vašáková, Brian D. Stewart, Divya Patel, (unknown), (unknown), Hiren J. Mehta, James R. Wright	4
5	Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors 2018 ·Molecular Cancer Therapeutics ·Apurva K. Srivastava, Melinda G. Hollingshead, Jeevan Prasaad Govindharajulu, Joseph M. Covey, Dane Liston, Melanie A. Simpson, James O. Peggins, Donald P. Bottaro, James R. Wright, Robert J. Kinders, James H. Doroshow, Ralph E. Parchment	7
6	Exposure–Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients 2017 ·Clinical Cancer Research ·(unknown), Vijay Ivaturi, Jogarao Gobburu, Jacqueline M. Greer, L. Austin Doyle, James R. Wright, Judith E. Karp, Michelle A. Rudek	9
7	Acute Toxicity and Quality of Life of Hypofractionated Radiation Therapy for Breast Cancer 2015 ·International Journal of Radiation OncologyBiologyPhysics ·Julie Arsenault, Sameer Parpia, Harold Reiter, (unknown), Himanshu Lukka, Eileen Rakovitch, James R. Wright, Jacob Julian, Timothy J. Whelan	5
8	A Phase I Study of DMS612, a Novel Bifunctional Alkylating Agent 2014 ·Clinical Cancer Research ·Leonard J. Appleman, Sanjeeve Balasubramaniam, Robert A. Parise, (unknown), Christophe E. Redon, Asako Nakamura, William M. Bonner, James R. Wright, Richard Piekarz, David Köhler, Yixing Jiang, Chandra P. Belani, Julie L. Eiseman, Edward Chu, Jan H. Beumer, Susan E. Bates	5
9	A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2 2013 ·Clinical Cancer Research ·Beata Holkova, Jeffrey G. Supko, Matthew M. Ames, Joel M. Reid, Geoffrey I. Shapiro, (unknown), Viswanathan Ramakrishnan, Mary Beth Tombes, (unknown), Renee M. McGovern, Maciej Kmieciak, Ellen Shrader, (unknown), Heidi Sankala, Austin Doyle, James R. Wright, John D. Roberts, Steven Grant	26
10	Phase I Study of the Combination of Sorafenib and Temsirolimus in Patients with Metastatic Melanoma 2012 ·Clinical Cancer Research ·Michael A. Davies, Patricia S. Fox, Nicholas E. Papadopoulos, Agop Y. Bedikian, Wen-Jen Hwu, Alexander J. Lazar, Víctor G. Prieto, Kirk S. Culotta, Timothy Madden, Quanyun A. Xu, Sha Huang, Wanleng Deng, Chaan S. Ng, Sanjay Gupta, Wenbin Liu, Janet Dancey, James R. Wright, Roland L. Bassett, Patrick Hwu, Kevin B. Kim	39
11	Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib 2011 ·Clinical Cancer Research ·Ronan J. Kelly, Arun Rajan, Jeremy Force, Ariel López-Chávez, (unknown), Liang Cao, Yunkai Yu, Peter L. Choyke, Barış Türkbey, Mark Raffeld, Liqiang Xi, Seth M. Steinberg, James R. Wright, Shivaani Kummar, Martin Gutierrez, Giuseppe Giaccone	58
12	Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer 2011 ·Clinical Cancer Research ·Athanassios Argiris, Austin G. Duffy, Shivaani Kummar, Nicole L. Simone, Yoshio Arai, (unknown), Susan F. Rudy, (unknown), Xinping Yang, Minyoung Jang, Zhong Chen, (unknown), (unknown), Susmita G. Ramanand, Aarif Ahsan, Mukesh K. Nyati, James R. Wright, Carter Van Waes	44
13	Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy 2010 ·Clinical Cancer Research ·James R. Wright	83
14	A novel small molecule with potent anticancer activity inhibits cell growth by modulating intracellular labile zinc homeostasis 2009 ·Molecular Cancer Therapeutics ·Mario Huesca, Lisa Lock, Aye Aye Khine, Stéphane Viau, Robert Peralta, (unknown), Hongnan Jin, Raed A. Al‐Qawasmeh, Yoon Lee, James R. Wright, Aiping Young	26
15	Phase II Trial of Sorafenib in Metastatic Thyroid Cancer 2009 ·Journal of Clinical Oncology ·Richard T. Kloos, Matthew D. Ringel, Michael V. Knopp, Nathan C. Hall, Mark A. King, Robert C. Stevens, Jiachao Liang, Paul E. Wakely, Vasyl Vasko, Motoyasu Saji, (unknown), Lai Wei, Daria Arbogast, Minden Collamore, James R. Wright, Michael R. Grever, Manisha H. Shah	430
16	Sins of our fathers: two of The Four Doctors and their roles in the development of techniques to permit covert autopsies. 2009 ·Archives of Pathology & Laboratory Medicine ·James R. Wright	11
17	A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer 2008 ·Clinical Cancer Research ·William L. Dahut, Charity D. Scripture, Edwin M. Posadas, Lokesh Jain, James L. Gulley, Philip M. Arlen, James R. Wright, Yunkai Yu, Liang Cao, Seth M. Steinberg, Jeanny B. Aragon‐Ching, Jürgen Venitz, Elizabeth C. Jones, Clara C. Chen, William D. Figg	142
18	Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide 2006 ·Journal of Clinical Oncology ·Joseph A. Sparano, Stacy L. Moulder, Aslamuzzaman Kazi, Linda T. Vahdat, Tianhong Li, Christine Pellegrino, P.N. Munster, Mokenge P. Malafa, David Lee, (unknown), Una Hopkins, Dawn L. Hershman, James R. Wright, Saı̈d M. Sebti	54
19	Tumor Necrosis Factor-α Drives 70% of Cigarette Smoke–induced Emphysema in the Mouse 2004 ·American Journal of Respiratory and Critical Care Medicine ·Andrew Churg, (unknown), Hsin Tai, Xiaoshan Wang, Changshi Xie, James R. Wright	285
20	Nitric Acid Oxidation of the Organic Matter of a Podzol 1960 ·Soil Science Society of America Journal ·M. Schnitzer, James R. Wright	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact